Aptus Pharma plans ₹44.88 crore raise for manufacturing and global expansion

Aptus Pharma proposes a preferential equity issue to fund manufacturing and storage capacity, working capital and distribution expansion. The company targets 20% in-house production and export growth across Africa, the Middle East and Latin America, subject to shareholder approval.

— Source publishedMon, 24 Aug, 2026, 14:46 IST·First seen Mon, 24 Aug, 2026, 15:06 IST·Source Business Today · Latest

What happened

Aptus Pharma plans to raise Rs 44.88 crore to build manufacturing and storage capacity, expand working capital and strengthen its balance sheet. It targets 20%

Key facts

  • Rs 44.88 crore preferential issue
  • Rs 25 crore for capital expenditure
  • Rs 10 crore for working capital
  • Rs 9.88 crore for general corporate purposes
  • 20% of product requirements targeted through in-house manufacturing
  • 1.99% stock rise
  • Rs 296.40 BSE intraday high
  • 36 months proposed fund utilisation

Why this matters

Aptus is building capabilities for broader Africa, Middle East and Latin America distribution, potentially creating partnership, licensing and supply-chain opportunities as its internal manufacturing footprint expands.

What to watch

  • Shareholder vote outcome and timeline for preferential allotment.
  • Final equity issue terms, including pricing, warrant structure, promoter participation and resulting dilution.
  • Capex commissioning milestones and evidence of incremental manufacturing/storage capacity.
  • In-house production share progressing toward 20%.
  • Gross-margin movement versus outsourced production costs.
  • Inventory days, receivable days and operating-cash-flow performance as distribution expands.
  • New export registrations, distributor agreements and geography-specific revenue disclosures.
  • Regulatory, currency, freight and payment-collection risks in export markets.
  • Seek shareholder approval for the preferential equity issue and disclose issue price, investor participation and dilution details.
  • Complete fundraise and allocate approximately ₹25 crore toward manufacturing and storage infrastructure.
  • Raise in-house production toward the stated 20% target, reducing external manufacturing dependence.
  • Expand working-capital support for inventory, receivables and distributor stocking.
  • Pursue export registrations, local distribution partnerships and order wins across Africa, the Middle East and Latin America.